Natus Medical Inc (NASDAQ:BABY) has earned an average recommendation of “Hold” from the six ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $42.50.
BABY has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 27th. BidaskClub downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Friday, July 13th. ValuEngine raised shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Roth Capital set a $36.00 price target on shares of Natus Medical and gave the company a “buy” rating in a report on Thursday, October 25th.
In related news, insider Jonathan Kennedy sold 47,600 shares of the stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $36.85, for a total value of $1,754,060.00. Following the completion of the transaction, the insider now owns 161,628 shares of the company’s stock, valued at approximately $5,955,991.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by company insiders.
Shares of NASDAQ:BABY traded down $1.41 during trading on Friday, reaching $29.94. The company’s stock had a trading volume of 26,848 shares, compared to its average volume of 310,742. The company has a current ratio of 3.21, a quick ratio of 2.31 and a debt-to-equity ratio of 0.28. Natus Medical has a 12 month low of $27.69 and a 12 month high of $43.30. The company has a market cap of $1.05 billion, a price-to-earnings ratio of 20.55 and a beta of 0.54.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, October 24th. The medical equipment provider reported $0.40 EPS for the quarter, missing the Zacks’ consensus estimate of $0.42 by ($0.02). Natus Medical had a negative net margin of 3.53% and a positive return on equity of 11.34%. The business had revenue of $130.60 million during the quarter, compared to the consensus estimate of $132.92 million. During the same period in the previous year, the business posted $0.40 EPS. The firm’s revenue was up 6.5% on a year-over-year basis. As a group, equities analysts forecast that Natus Medical will post 1.48 EPS for the current year.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: Growth Stocks
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.